{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:42:02Z","timestamp":1786502522910,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03681-3","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T20:22:02Z","timestamp":1558556522000},"page":"1547-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and\/or paroxysmal nocturnal haemoglobinuria (QLQ-AA\/PNH)\u2014a report on phase III"],"prefix":"10.1007","volume":"98","author":[{"given":"Cathrin","family":"Niedeggen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Petermann-Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"H\u00f6chsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-3112","authenticated-orcid":false,"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"issue":"8","key":"3681_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26(8):1547\u20131573. https:\/\/doi.org\/10.1093\/annonc\/mdv249","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"3681_CR2","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A, Group EQoL, Quality of Life U (2002) Quality of life research within the EORTC-the EORTC QLQ-C30.. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4):S125\u2013S133","journal-title":"Eur J Cancer"},{"issue":"18","key":"3681_CR3","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.ejca.2015.08.027","volume":"51","author":"C Quinten","year":"2015","unstructured":"Quinten C, Coens C, Ghislain I, Zikos E, Sprangers MA, Ringash J, Martinelli F, Ediebah DE, Maringwa J, Reeve BB, Greimel E, King MT, Bjordal K, Flechtner HH, Schmucker-Von Koch J, Taphoorn MJ, Weis J, Wildiers H, Velikova G, Bottomley A, Probe, Groups EC (2015) The effects of age on health-related quality of life in cancer populations: a pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer 51(18):2808\u20132819. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.027","journal-title":"Eur J Cancer"},{"issue":"9","key":"3681_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/hed.23127","volume":"35","author":"S Singer","year":"2013","unstructured":"Singer S, Arraras JI, Baumann I, Boehm A, Chie WC, Galalae R, Langendijk JA, Guntinas-Lichius O, Hammerlid E, Pinto M, Nicolatou-Galitis O, Schmalz C, Sen M, Sherman AC, Spiegel K, Verdonck-de Leeuw I, Yarom N, Zotti P, Hofmeister D, Group EQoL, Head E, Neck Cancer G (2013) Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy\u2014update of the EORTC QLQ-H&N35, phase I. Head Neck 35(9):1331\u20131338. https:\/\/doi.org\/10.1002\/hed.23127","journal-title":"Head Neck"},{"issue":"4","key":"3681_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ijrobp.2016.11.051","volume":"97","author":"K Bjordal","year":"2017","unstructured":"Bjordal K, Bottomley A (2017) Making advances in quality of life studies in head and neck cancer. Int J Radiat Oncol Biol Phys 97(4):659\u2013661. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"3681_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3109\/10428194.2012.662643","volume":"53","author":"A Alegre","year":"2012","unstructured":"Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rosettani B (2012) Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 53(9):1714\u20131721. https:\/\/doi.org\/10.3109\/10428194.2012.662643","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3681_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/pon.4127","volume":"26","author":"A Bredart","year":"2017","unstructured":"Bredart A, Beaudeau A, Young T, Moura De Alberquerque Melo H, Arraras JI, Friend L, Schmidt H, Tomaszewski KA, Bergenmar M, Anota A, Costantini A, Marchal F, Tomaszewska IM, Vassiliou V, Chie WC, Hureaux J, Conroy T, Ramage J, Bonnetain F, Kulis D, Aaronson NK, Group EQoL (2017) The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development. Psycho-oncology 26(3):400\u2013404. https:\/\/doi.org\/10.1002\/pon.4127","journal-title":"Psycho-oncology"},{"issue":"8","key":"3681_CR8","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1007\/s00520-016-3270-7","volume":"24","author":"V Ganesh","year":"2016","unstructured":"Ganesh V, Agarwal A, Popovic M, Cella D, McDonald R, Vuong S, Lam H, Rowbottom L, Chan S, Barakat T, DeAngelis C, Borean M, Chow E, Bottomley A (2016) Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer 24(8):3661\u20133668. https:\/\/doi.org\/10.1007\/s00520-016-3270-7","journal-title":"Support Care Cancer"},{"issue":"3","key":"3681_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825\u2013836. https:\/\/doi.org\/10.1007\/s11136-013-0523-5","journal-title":"Qual Life Res"},{"key":"3681_CR10","unstructured":"List of rare diseases and synonyms listed in alphabetical order (2017) Orphanet Report Series, Rare Diseases collection"},{"issue":"5","key":"3681_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ejon.2007.09.004","volume":"11","author":"J Griffiths","year":"2007","unstructured":"Griffiths J, Willard C, Burgess A, Amir Z, Luker K (2007) Meeting the ongoing needs of survivors of rarer cancer. Eur J Oncol Nurs 11(5):434\u2013441. https:\/\/doi.org\/10.1016\/j.ejon.2007.09.004","journal-title":"Eur J Oncol Nurs"},{"key":"3681_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-90-481-9485-8_22","volume":"686","author":"B Gulbis","year":"2010","unstructured":"Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surralles J, Castella M, Heimpel H, Hill A, Corrons JL (2010) Epidemiology of rare anaemias in Europe. Adv Exp Med Biol 686:375\u2013396. https:\/\/doi.org\/10.1007\/978-90-481-9485-8_22","journal-title":"Adv Exp Med Biol"},{"key":"3681_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/asheducation-2010.1.36","volume":"2010","author":"JR Passweg","year":"2010","unstructured":"Passweg JR, Marsh JC (2010) Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology 2010:36\u201342. https:\/\/doi.org\/10.1182\/asheducation-2010.1.36","journal-title":"Hematology"},{"issue":"7","key":"3681_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.7326\/0003-4819-136-7-200204020-00011","volume":"136","author":"NS Young","year":"2002","unstructured":"Young NS (2002) Acquired aplastic anemia. Ann Intern Med 136(7):534\u2013546","journal-title":"Ann Intern Med"},{"issue":"4","key":"3681_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.exphem.2007.01.046","volume":"35","author":"CJ Parker","year":"2007","unstructured":"Parker CJ (2007) The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol 35(4):523\u2013533. https:\/\/doi.org\/10.1016\/j.exphem.2007.01.046","journal-title":"Exp Hematol"},{"issue":"1","key":"3681_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.seminhematol.2014.10.002","volume":"52","author":"R Desmond","year":"2015","unstructured":"Desmond R, Townsley DM, Dunbar C, Young NS (2015) Eltrombopag in aplastic anemia. Semin Hematol 52(1):31\u201337. https:\/\/doi.org\/10.1053\/j.seminhematol.2014.10.002","journal-title":"Semin Hematol"},{"issue":"22","key":"3681_CR17","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1182\/blood-2013-05-498279","volume":"122","author":"JC Marsh","year":"2013","unstructured":"Marsh JC, Kulasekararaj AG (2013) Management of the refractory aplastic anemia patient: what are the options? Blood 122(22):3561\u20133567. https:\/\/doi.org\/10.1182\/blood-2013-05-498279","journal-title":"Blood"},{"issue":"6","key":"3681_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","volume":"120","author":"P Scheinberg","year":"2012","unstructured":"Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120(6):1185\u20131196. https:\/\/doi.org\/10.1182\/blood-2011-12-274019","journal-title":"Blood"},{"issue":"19","key":"3681_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV (1995) Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333(19):1253\u20131258. https:\/\/doi.org\/10.1056\/NEJM199511093331904","journal-title":"N Engl J Med"},{"issue":"9027","key":"3681_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","volume":"348","author":"G Socie","year":"1996","unstructured":"Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E (1996) Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 348(9027):573\u2013577","journal-title":"Lancet"},{"issue":"1","key":"3681_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2141.2004.04992.x","volume":"126","author":"VM Moyo","year":"2004","unstructured":"Moyo VM, Mukhina GL, Garrett ES, Brodsky RA (2004) Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 126(1):133\u2013138. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04992.x","journal-title":"Br J Haematol"},{"issue":"3","key":"3681_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","volume":"83","author":"J Nishimura","year":"2004","unstructured":"Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, Decastro CM, Hall S, Kanamaru A, Sullivan KM, Mizoguchi H, Omine M, Kinoshita T, Rosse WF (2004) Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83(3):193\u2013207","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3681_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socie G, Brodsky RA (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162(1):62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347","journal-title":"Br J Haematol"},{"issue":"12","key":"3681_CR24","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233\u20131243. https:\/\/doi.org\/10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"issue":"4","key":"3681_CR25","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111(4):1840\u20131847. https:\/\/doi.org\/10.1182\/blood-2007-06-094136","journal-title":"Blood"},{"issue":"5","key":"3681_CR26","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Socie G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P (2014) Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 99(5):922\u2013929. https:\/\/doi.org\/10.3324\/haematol.2013.093161","journal-title":"Haematologica"},{"issue":"5","key":"3681_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/BF00844815","volume":"16","author":"B Curbow","year":"1993","unstructured":"Curbow B, Somerfield MR, Baker F, Wingard JR, Legro MW (1993) Personal changes, dispositional optimism, and psychological adjustment to bone marrow transplantation. J Behav Med 16(5):423\u2013443","journal-title":"J Behav Med"},{"issue":"2","key":"3681_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF01857605","volume":"19","author":"MR Somerfield","year":"1996","unstructured":"Somerfield MR, Curbow B, Wingard JR, Baker F, Fogarty LA (1996) Coping with the physical and psychosocial sequelae of bone marrow transplantation among long-term survivors. J Behav Med 19(2):163\u2013184","journal-title":"J Behav Med"},{"issue":"3","key":"3681_CR29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.2000.02452.x","volume":"111","author":"M Eapen","year":"2000","unstructured":"Eapen M, Ramsay NK, Mertens AC, Robison LL, DeFor T, Davies SM (2000) Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol 111(3):754\u2013760","journal-title":"Br J Haematol"},{"issue":"1","key":"3681_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2141.1989.tb00230.x","volume":"73","author":"MM de Planque","year":"1989","unstructured":"de Planque MM, Bacigalupo A, Wursch A, Hows JM, Devergie A, Frickhofen N, Brand A, Nissen C (1989) Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol 73(1):121\u2013126","journal-title":"Br J Haematol"},{"issue":"11","key":"3681_CR31","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood.V76.11.2222.2222","volume":"76","author":"Y Najean","year":"1990","unstructured":"Najean Y, Haguenauer O (1990) Long-term (5 to 20 years) evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias. Blood 76(11):2222\u20132228","journal-title":"Blood"},{"key":"3681_CR32","unstructured":"Johnson C, Aaronson N, Blazeby J, Bottomley A, Fayers P, Koller M, Kuli\u015b D, Ramage J, Sprangers M, Velikova G, Young T (2011) Guidelines for developing questionnaire modules EORTC Quality of Life Department, Ave E Mounier 83, B.11, 1200 Brussels, BELGIUM, Tel: +32 (0)2 774 1678"},{"issue":"2","key":"3681_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00277-016-2867-8","volume":"96","author":"M Groth","year":"2017","unstructured":"Groth M, Singer S, Niedeggen C, Petermann-Meyer A, Roth A, Schrezenmeier H, Hochsmann B, Brummendorf TH, Panse J (2017) Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria (QLQ-AA\/PNH)-report on phases I and II. Ann Hematol 96(2):171\u2013181. https:\/\/doi.org\/10.1007\/s00277-016-2867-8","journal-title":"Ann Hematol"},{"key":"3681_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-9-32","volume":"9","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, Lampe C (2014) Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis 9:32. https:\/\/doi.org\/10.1186\/1750-1172-9-32","journal-title":"Orphanet J Rare Dis"},{"key":"3681_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0366-y","volume":"10","author":"S Van Groenendael","year":"2015","unstructured":"Van Groenendael S, Giacovazzi L, Davison F, Holtkemper O, Huang Z, Wang Q, Parkinson K, Barrett T, Geberhiwot T (2015) High quality, patient centred and coordinated care for Alstrom syndrome: a model of care for an ultra-rare disease. Orphanet J Rare Dis 10:149. https:\/\/doi.org\/10.1186\/s13023-015-0366-y","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3681_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"3681_CR37","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ejca.2007.05.029","volume":"43","author":"M Koller","year":"2007","unstructured":"Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, Johnson C, Ramage J, Scott N, West K, Group EQoL (2007) Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 43(12):1810\u20131820. https:\/\/doi.org\/10.1016\/j.ejca.2007.05.029","journal-title":"Eur J Cancer"},{"issue":"12","key":"3681_CR38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","volume":"14","author":"BP Morgan","year":"2015","unstructured":"Morgan BP, Harris CL (2015) Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 14(12):857\u2013877. https:\/\/doi.org\/10.1038\/nrd4657","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3681_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.smim.2016.05.001","volume":"28","author":"AM Risitano","year":"2016","unstructured":"Risitano AM, Marotta S (2016) Therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future. Semin Immunol 28(3):223\u2013240. https:\/\/doi.org\/10.1016\/j.smim.2016.05.001","journal-title":"Semin Immunol"},{"issue":"16","key":"3681_CR40","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS (2017) Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376(16):1540\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1613878","journal-title":"N Engl J Med"},{"issue":"5","key":"3681_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.outlook.2014.05.009","volume":"62","author":"M Bevans","year":"2014","unstructured":"Bevans M, Ross A, Cella D (2014) Patient-Reported Outcomes Measurement Information System (PROMIS): efficient, standardized tools to measure self-reported health and quality of life. Nurs Outlook 62(5):339\u2013345. https:\/\/doi.org\/10.1016\/j.outlook.2014.05.009","journal-title":"Nurs Outlook"},{"issue":"1","key":"3681_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00520-007-0270-7","volume":"16","author":"LI Wagner","year":"2008","unstructured":"Wagner LI, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, Cella D (2008) Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N). Support Care Cancer 16(1):47\u201356. https:\/\/doi.org\/10.1007\/s00520-007-0270-7","journal-title":"Support Care Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03681-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03681-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03681-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T12:03:35Z","timestamp":1721304215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03681-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03681-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data protection official of the University Hospital RWTH Aachen and the Institutional Review Board of the Medical Faculty RWTH Aachen University approved the study protocol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}